MCG Health and the $50 million case for better paperwork

In February 2025, NYC Health + Hospitals announced a result that deserves a place beside the more glamorous hospital success stories. Over two years, it had cut its rate of inpatient insurance claim denials in half. In one fiscal year, it reported savings of $50 million. Part of the intervention was MCG Health software. Another part was teaching a large organization to explain itself more precisely.

A patient could be ill enough to need a hospital bed, yet the documentation could fail to make the case. In medicine, the facts matter. In reimbursement, where those facts appear and how clearly they support the decision matter too. MCG occupies that awkward meeting point.

The diagnosis was only half the argument

The New York team began with the diseases generating the most denials, including chest pain, appendicitis, sepsis and cholecystitis. It created alerts and templates that helped capture the details supporting medical necessity. Training brought clinical departments, case management, finance and hospital leadership into the same conversation.

The intriguing detail is the full-day retreats. A software purchase is easier to announce than a day spent getting departments to agree on documentation. Yet the result was attributed to both MCG and internal process changes. It offers a useful lesson for buyers: the tool needs an organization willing to change how it works.

A binder with unusually long legs

MCG began inside Milliman in 1988, where actuarial work met clinical evidence. Richard L. Doyle wrote the first care guidelines, distributed in a three-ring notebook. An insurer could consult the same reference repeatedly; hospitals later became customers too. Eventually, the reference moved into software.

The binder is a revealing ancestor. A guideline publisher must decide which evidence deserves a reader’s attention. A workflow vendor must also decide when that evidence should appear. Moving from the shelf to the clinical review screen changes the product’s usefulness: the reference can accompany a decision while someone is documenting it.

Hearst acquired the business in 2012. Today, MCG sits within Hearst Health. It is a peculiar publishing story, with an entirely practical logic. The valuable material is specialized information that people need often, in circumstances where a poorly supported decision can become expensive.

The same evidence, two different desks

MCG sells to organizations whose interests sometimes collide. A hospital wants its inpatient care recognized and reimbursed. A health plan wants to assess whether the requested service is appropriate. Each needs clinical support for its position. A shared reference gives them something specific to discuss.

The product families reflect those jobs. Indicia supports hospital review and documentation. CareWebQI supports payer utilization management. Coordinate covers care planning and transitions. AutoAuth supports prior authorization. ODG adds workers’ compensation expertise. Buyers can license content and software, with training and integration around them.

InterQual, offered by Optum, is a direct alternative. MCG makes its ownership outside a health plan or provider organization part of its pitch. That distinction invites buyers to examine how criteria are developed, who reviews them and how disagreements are handled. Ownership alone cannot settle those questions.

MCG reported more than 3,200 hospital customers in March 2026. That reach makes it established infrastructure in a specialized market. The everyday users are reviewers, medical directors and case managers, people whose work rarely earns a splashy product launch.

The fax machine’s natural enemy

Regence’s account of its work with MultiCare describes the old authorization routine: faxed requests, separate portals and re-entered clinical information. Each transfer creates another opportunity for error or delay. Making the reviewer faster leaves much of that journey intact.

The partnership put authorization requests inside the electronic health record using FHIR, a standard for exchanging healthcare information. MCG participated in the collaboration. The important change was a direct connection between organizations, built into the place where the work already happened.

“we need to be interoperable with our providers”Heidi Kriz, Regence, describing the impetus for the project at AHIP 2023

That observation helps explain MCG Path, which supplies guideline criteria through FHIR-based interfaces. In September 2026, MCG announced a certified integration with sibling Hearst Health company MHK. It connects Path with MHK’s CareProminence authorization workflow. A useful reference becomes more useful when nobody has to leave the task to consult it.

AI has to show its work

MCG’s assistive AI has a related ambition: reduce the work of finding relevant clinical information. Synapse supports that extraction and comparison with guideline indications. Its appeal is easy to understand. A reviewer should spend time assessing the case, with less time hunting through the record.

The harder question is whether the system finds the right details. MCG describes testing against encounters labelled by clinical experts and reviewing disagreements. That is the part of the AI story buyers should interrogate: what counts as a correct answer, and who decides?

The distinction becomes consequential with incomplete records or unusual cases. A confident summary is only helpful when its underlying evidence can be checked. A benchmark can flag a question; the patient’s circumstances still determine whether the apparent variation needs an explanation.

Trust has more than one balance sheet

MCG’s history also contains a data incident discovered in March 2022. The court-authorized settlement website describes an unauthorized party obtaining personal and protected health information. It states that the acquisition date was unknown, with evidence suggesting February 2020.

The litigation produced an $8.8 million settlement fund. Clinical evidence and information security are separate obligations. A company can devote considerable effort to one and still face a serious failure in the other. For a buyer, both belong in the assessment of a system handling clinical information.

Buy the workflow, budget for the people

A sensible purchasing conversation starts with a specific problem. Are reviewers missing the clinical facts supporting admission? Are requests being retyped between systems? Do different staff members apply the same guideline differently? Those problems suggest different interventions, even when one vendor offers tools for all of them.

The New York example gives readers something concrete to copy: start with denial-heavy diagnoses, improve the record and train the departments together. For an AI project, add a way to inspect incorrect outputs. For an integration project, check that the receiving organization can use what is sent.

MCG’s public product pages direct purchasers to licensing inquiries and demonstrations. Any budget should also allow for integration, training and ongoing review. The $50 million customer result is a reason to study the work, not a substitute for calculating the cost of doing it locally.

The approach depends on usable records, applicable coverage criteria and people prepared to question the output. A guideline cannot supply a missing patient detail. Nor can a software installation make two organizations agree. MCG’s most persuasive story is the one in which its evidence gives a capable team a better way to make its case.